VOLITIONRX LTD (VNRX): Other Events
VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027 Reduces Equity Overhang Henderson, Nevada, September 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-n
How this was made
The 30-second read
Why it matters
The repayment eliminates $7.5 M of future dilution risk and improves the balance sheet, likely providing short‑term price support.
Market read
A primary corporate‑action disclosure for a micro‑cap; modest relevance for traders monitoring debt‑related catalysts.
What to watch
Potential hidden covenant implications or future financing needs not disclosed.
Background
VolitionRx is a multinational epigenetics firm listed on NYSE American (VNRX). The filing reports a cash pre‑payment of a previously issued convertible note.
Ticker impact
VolitionRx disclosed full pre‑payment of a $7.5 million senior secured convertible note, reducing dilution risk and improving balance‑sheet strength.
Modest upside potential as cash repayment removes future dilution.
The cash pre‑payment is a primary corporate‑action event; the amount is modest for a micro‑cap, so impact is limited but clear.
Market effects
Minimal; debt‑reduction signal may be noted by niche epigenetics investors.
None
Low
Counterpoint
The repayment could signal cash constraints, suggesting the company may face liquidity pressure.
Key entities
- companyVolitionRx Ltd.
Epigenetics biotech issuing the note.
- creditorLind Global Asset Management XII LLC
Holder of the prepaid convertible note.
